PSIL - Psychedelics Closer To Commercialization; Compass Far And Away The Leader

2024-05-23 12:15:00 ET

Summary

• Regulatory risk in the psychedelic industry is decreasing, which is a positive sign for investors.
• Institutional investors are becoming more willing to invest in leading psychedelic companies through private placements.
• Analyst Alex Carchidi discusses Compass, Cybin, Atai, and MindMed seeing improvements in their balance sheets and clinical trial data.

Listen here or on the go via Apple Podcasts and Spotify

Analyst Alex Carchidi discusses positive news coming out of psychedelic space (1:00). Recent earnings show companies moving closer to commercialization (3:35). Cybin and Atai developments; clinical studies and regulatory relief (5:25). Why now is the time to get into the space; ranking Compass and MindMed above the rest (8:00). Proper metrics and diversified pipelines (10:20).

Transcript

Rena Sherbill: Alex Carchidi, welcome back to the Cannabis Investing Podcast. Always great to talk to you. Thanks for coming back on the show....

For further details see: